Krystal Biotech, Inc. $KRYS Holdings Boosted by Odyssean LLC

Odyssean LLC boosted its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 94.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 9,349 shares of the company’s stock after buying an additional 4,530 shares during the quarter. Krystal Biotech makes up about 0.6% of Odyssean LLC’s investment portfolio, making the stock its 10th largest holding. Odyssean LLC’s holdings in Krystal Biotech were worth $3,475,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in KRYS. Jupiter Topco LLC bought a new position in Krystal Biotech in the second quarter worth approximately $95,387,000. Elmind Capital LP purchased a new stake in shares of Krystal Biotech in the 2nd quarter worth $8,176,740. ADAR1 Capital Management LLC purchased a new stake in shares of Krystal Biotech in the 2nd quarter worth $6,103,000. Hsbc Holdings PLC purchased a new stake in shares of Krystal Biotech in the 2nd quarter worth $3,653,000. Finally, EFG International AG bought a new position in Krystal Biotech in the 2nd quarter worth $5,688,000. 86.29% of the stock is owned by hedge funds and other institutional investors.

Krystal Biotech Stock Performance

Shares of Krystal Biotech stock opened at $358.24 on Friday. Krystal Biotech, Inc. has a fifty-two week low of $136.73 and a fifty-two week high of $382.54. The company has a market capitalization of $10.60 billion, a P/E ratio of 44.89 and a beta of 0.54. The company has a fifty day moving average of $349.81 and a 200 day moving average of $307.38.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, August 3rd. The company reported $1.79 EPS for the quarter, beating analysts’ consensus estimates of $1.70 by $0.09. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%.The business had revenue of $119.22 million for the quarter, compared to analysts’ expectations of $120.93 million. Analysts forecast that Krystal Biotech, Inc. will post 7.48 EPS for the current year.

Insider Buying and Selling

In related news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $359.32, for a total value of $8,983,000.00. Following the transaction, the insider directly owned 1,302,145 shares of the company’s stock, valued at approximately $467,886,741.40. The trade was a 1.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Dino A. Rossi sold 25,000 shares of the company’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $329.12, for a total value of $8,228,000.00. Following the completion of the transaction, the director owned 50,000 shares of the company’s stock, valued at $16,456,000. The trade was a 33.33% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 51,000 shares of company stock worth $17,558,270. 13.10% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on KRYS shares. Royal Bank Of Canada assumed coverage on Krystal Biotech in a research report on Friday, August 14th. They set an “outperform” rating and a $400.00 target price on the stock. Bank of America raised their price objective on Krystal Biotech from $364.00 to $396.00 and gave the stock a “buy” rating in a research note on Tuesday, July 14th. Weiss Ratings downgraded Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a research note on Tuesday, August 18th. Wall Street Zen downgraded Krystal Biotech from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. Finally, Citigroup raised their target price on shares of Krystal Biotech from $378.00 to $386.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $365.40.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.